- Case report
- Open Access
Aggressive primary gastric lymphoma (PGL) masquerading as hepatocellular cancer (HCC) in alcoholic cirrhosis
BMC Gastroenterology volume 21, Article number: 104 (2021)
The gastrointestinal tract is sa well-known site for extranodal Non-Hodgkin lymphomas, with the stomach is known to be the most common site on lymphoma, primary gastric lymphoma (PGL). The lymphoproliferative disorder rarely occurs in patients with cirrhosis. We report a unique case of metastatic PGL in a patient with cirrhosis.
A middle-aged male with decompensated alcoholic cirrhosis presented with two weeks of epigastric abdominal pain, abdominal distension, and jaundice. Abdominal triple-phase CT scan was consistent with cirrhosis, ascites, and multiple new hypodense liver lesions classified as an intermediate probability for HCC based on the LI-RADS classification system (LI RADS 3). Due to the CT findings in the setting of cirrhosis, a provisional diagnosis of HCC was made. Upper endoscopy revealed new multiple umbilicated submucosal nodules in the gastric body. Biopsy and immunostaining consistent with high-grade B-cell lymphoma. Targeted liver biopsy with similar morphology and immunostaining profile consistent with metastatic primary gastric DLBCL.
The case highlights the importance of recognizing metastatic PGL in patients with underlying cirrhosis to differentiate lymphoma from hepatocellular cancer. Targeted liver biopsies with lymphoma immunostaining are required to make a diagnosis.
The gastrointestinal (GI) tract is a well-known site for extra nodal Non-Hodgkin lymphomas, representing 30–40% of all extra nodal lymphomas. The stomach is known to be the most common site followed by the small intestine and the colorectum. Potential risk factors for extra nodal Non-Hodgkin lymphomas include infections such as H. pylori, HIV, Hepatitis B, HTLV, and noninfectious diseases such as celiac disease, IBD, SLE, and immunosuppression . The development of chronic liver disease and cirrhosis in patients with the pre-existing lymphoproliferative disorder has been well described. However, the development of lymphoma in patients with cirrhosis is extremely rare. This carries a diagnostic challenge and creates confusion among many clinicians that can be mistakenly diagnosed as HCC. We describe a unique and rare case of metastatic primary gastric lymphoma in patients with alcoholic cirrhosis.
A 55-year-old male with a past medical history of anemia and long-standing alcohol abuse with recent diagnosis of cirrhosis (Child’s Pugh Score B, MELD-Na 22) decompensated by portal hypertension in form of abdominal ascites, and medium-size esophageal varices, presented with 2 weeks of worsening epigastric abdominal pain and distention. The patient drinks six cans of beer daily for 10 years. Denies smoking or eliciting recreational drugs. No prior surgical intervention. On physical examination, the patient looks cachectic. He has minimal scleral icterus and trace lower extremities edema. Abdominal examination notable for a mild epigastric tenderness and abdominal distention with shifting dullness. His laboratory data demonstrates complete blood count (CBC) with WBC 8. 7 K/MCL, hemoglobin (Hb) 9.1 gm/dl, Hct 26.8%, and platelets 46 k/MCL. The coagulation panel demonstrates an INR of 2.0. Abnormal liver chemistry, alanine transaminase (ALT) of 44 IU/ml, aspartate aminotransferase (AST) of 67 IU/ml, alkaline phosphatase (ALP) of 253 mg/dl, and a total bilirubin 5.2 mg/dl (direct bilirubin 3.8). The work-ups for abnormal liver chemistry were unremarkable including viral hepatitis A, B and C. Abdominal triple-phase CT was noteworthy for cirrhosis, mild to moderate ascites, and multiple new hypodense lesions throughout the liver, the largest being a 6 cm in diameter in the right lobe. The lesions were classified as an intermediate probability for HCC based on the LI-RADS classification system (LI RADS 3) (Fig. 1a, b). The tumor marker for AFP was normal. Three months before admission the patient had an unremarkable upper endoscopy (EGD) and colonoscopy for an indication of iron deficiency anemia (IDA) which demonstrates no obvious luminal lesion. The hospital course was complicated by upper gastrointestinal bleeding with hematemesis required blood transfusion. Diagnostic EGD showed large non-bleeding esophageal varices, severe portal hypertensive gastropathy (PHG), and multiple new umbilicated, ulcerated, firm, submucosal nodules throughout the gastric body (Fig. 2). Targeted liver biopsy performed given the suspicious radiological liver features for HCC in the background of cirrhosis Biopsy of the submucosal gastric nodules revealed high-grade B-cell lymphoma involving the lamina propria, without evidence of Helicobacter Pylori. Neoplastic cells were positive for CD20, Pax-5, BCL-6, CD10, BCL-2, and negative for CD3. Ki67 index was 95% positive for lymphoma cells (Figs. 3a, b, 4). Further, tumor markers including carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 which were normal. The cell morphology and immunostaining profile of the liver biopsy was identical to the gastric submucosal nodules, thus confirming the diagnosis of primary gastric DLBCL with metastasis to the liver (Figs. 3b, 4). The patient received one session of chemotherapy with low-dose Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) knowing that lymphoma is chemosenstive tumor and patient continues to have stable bilirubin since hospital admission (MELD-Na 21). Unfortunately, his bilirubin levels started to rise up to 25 mg/dl over 3 weeks period. His hospital course was complicated with septic shock secondary to SBP and disseminated intravascular coagulation (DIC) resulting in his death.
Discussion and conclusions
Primary gastric lymphoma constitutes < 5% of all primary gastric neoplasms. The GI tract accounts for 30–40% of all extra nodal non-Hodgkin’s lymphomas, making it the most common extra-nodal site . Primary gastric lymphoma encompasses a spectrum of diseases ranging from indolent low-grade marginal lymphoma to mucosa-associated lymphoid tissue (MALT) lymphomas, to aggressive diffuse B cell lymphomas (DBCL) .
The incidence of large B cell lymphoma in the general population is 5–7 cases per 100,000 cases per year while the incidence of DBCL in cirrhosis is extremely rare with no clear actual incidence in literature [3, 4]. It has been postulated in previous studies that dysregulation in immune function contributes to the disease process. Specifically, chronic antigen stimulation contributes to the development of lymphoproliferative disorders leading to monoclonal gammopathy. Viral hepatitis may also be a source for antigen stimulation in the case of Hepatitis B . Similarly, H. pylori is also thought to cause antigenic stimulation that can lead to monoclonal gammopathy and eventually to malignant lymphoproliferative disorder. Platin based chemotherapy has been described as a risk factor for lymphoma in cirrhotic patients treated for HCC . To our knowledge, there is no clear correlation between lymphoproliferative disorder such lymphoma and cirrhosis in the absence of antigenic stimulation (viral hepatitis B & C).
The clinical presentation of PGL is nonspecific, however, abdominal pain and weight loss are the most common manifestations. Gastrointestinal bleeding due to lymphoma cells infiltrating into the stomach can occur and, in some instances, may lead to perforation [7, 8]. A more dramatic presentation can be seen in patients with decompensated cirrhosis especially with underlying coagulopathy from chronic liver disease. According to the Lugano classification of DBCL, isolated stomach involvement denotes localized disease. Distant metastasis with advanced lymphoma involves the liver as in our case causing multiple hepatic lesion resembling metastatic HCC. These hepatic lesions lack the radiologic characteristic of HCC such as arterial enhancement, pseudo capsule, and washout further supporting lymphoma as the etiology for the clinical findings.
Diagnostic imaging with a cross-sectional CT scan is necessary to stage disease . A positron emission tomography (PET) scan is helpful as it can demonstrate an uptake in the stomach and the liver to express tumor activity but it won’t provide tissue diagnosis to differentiate synchronous versus metachronous tumor. Endoscopic ultrasound may play a role in early disease (stage I, II) . The treatment of PGL includes chemotherapy, surgical resection, and some instances radiation therapy. Anti-CD-20 monoclonal antibody with Rituximab in combination with CHOP therapy is a mainstay treatment approach for patients with lymphoma. R-CHOP made DBCL a curable disease with a good prognosis with a five to ten-year survival rate approaching 55% . Surgical resection is curative especially for localized disease [2, 9]. Certain considerations are crucial for such patients with cirrhosis such as MELD-Na score prior to considering chemotherapy treatment and evaluating patient’s surgical candidacy according to the Child’s Pugh A classification. The overall disease prognosis, five to ten-year mortality rate for PGL stage I, 87% and stage II, 60% . The 3 year survival rate for stage III & IV is 43–65% [9, 11]. Prognosis expect to be lower in the presence of cirrhosis but there is no clear literature evidence as of yet.
In conclusion, we report a case of PGL with metastasis to the liver in a patient with decompensated cirrhosis. This case depicts the diagnostic uncertainty of recognizing metastatic PGL in patients with underlying cirrhosis. It highlights the importance of targeted liver biopsies in patients with cirrhosis with liver lesions and normal AFP values.
Availability of data and materials
Primary Gastric lymphoma
Extra-nodal Non-Hodgkin lymphomas
Inflammatory bowel disease
Systemic lupus erythematosus
Human T-lymphotropic virus
Portal hypertensive gastropathy
Mucosa-associated lymphoid tissue lymphoma
Diffuse B cell lymphoma
European Committee on Antimicrobial Susceptibility Testing
Rituximab-Cyclophosphamide, Doxorubicin, Hydrochloride, Hydroxy daunomycin and Vincristine Sulfate
Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomark Prev. 2007;16(3):401–4.
Lombardo L, Rota Scalabrini D, Vineis P, De La Pierre M. Malignant lymphoproliferative disorders in liver cirrhosis. Ann Oncol. 1993;4(3):245–50.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–76.
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–92.
Shapira MY, Muszkat M, Braunstein I, Gotsman I. Co-occurrence of hepatocellular carcinoma and lymphoma in patients with hepatitis C virus cirrhosis. J Clin Gastroenterol. 2001;32(4):368–9.
Matsuo I, Omagari K, Ikuno N, Kinoshita H, Onizuka Y, Itsuno M, Nakayama T, Kohno S. Malignant lymphoma of the stomach after chemotherapy for hepatocellular carcinoma. J Gastroenterol. 1997;32(4):533.
Zeng C, Luo S, Lv N, Chen Y. Refractory peptic ulceration following radiation therapy in primary gastric lymphoma: a report of two cases. Oncol Lett. 2015;9(1):63–6.
Shirwaikar Thomas A, Schwartz M, Quigley E. Gastrointestinal lymphoma: the new mimic. BMJ Open Gastroenterol. 2019;6(1):e000320.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–67.
Schizas D, Ntanasis-Stathopoulos I, Tsilimigras DI, Sioulas AD, Moris D, Spartalis E, Scotiniotis I, Papanikolaou IS. The role of endoscopic ultrasound in the diagnosis and management of primary gastric lymphoma. Gastroenterol Res Pract. 2017;2017:2397430.
Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, Takahashi H, Lennert K. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991;101(5):1159–70.
Dr. Robert Blue, interventional radiologist at Icahn School of Medicine (Elmhurst) for providing cross sectional imaging.
All authors declare that there is no funding to this publication.
Ethics approval and consent to participate
Consent for publication
Formal written consent was obtained from patient’s brother for any clinical details and relative images.
All authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ahmed, M., Al-Khazraji, A., Syed, U. et al. Aggressive primary gastric lymphoma (PGL) masquerading as hepatocellular cancer (HCC) in alcoholic cirrhosis. BMC Gastroenterol 21, 104 (2021). https://doi.org/10.1186/s12876-021-01691-y
- Primary gastric lymphoma
- Hepatocellular carcinoma HCC
- Case report